Zobrazeno 1 - 10
of 152
pro vyhledávání: '"Michele Del, Vecchio"'
Autor:
Paolo A. Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandalà, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbe, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero, Antonio M. Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni, Giuseppe Palmieri
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract No prospective data were available prior to 2021 to inform selection between combination BRAF and MEK inhibition versus dual blockade of programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) as first-line treat
Externí odkaz:
https://doaj.org/article/2b98c18ea9d84e45baec87cc1752497f
Autor:
Dirk Schadendorf, Caroline Robert, Reinhard Dummer, Luis de la Cruz-Merino, Paolo A Ascierto, John M Kirkwood, Georgina V Long, Jacek Mackiewicz, Richard A Scolyer, Piotr Rutkowski, Jean-Jacques Grob, Jason John Luke, Michele Del Vecchio, Mizuho Kalabis, Adnan Khattak, Matteo S Carlino, Yujie Zhao, Alexander Eggermont, Vanna Chiarion Sileni, Clemens Krepler
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus placebo in the phase 3 KEYNOTE-716 study of resected stage IIB or IIC melanoma. At the prespecified third inter
Externí odkaz:
https://doaj.org/article/3a3ddc48ec6449b2b77882fcccc4b11b
Autor:
Elena Muraro, Barbara Montico, Benedict Lum, Francesca Colizzi, Giorgio Giurato, Annamaria Salvati, Roberto Guerrieri, Aurora Rizzo, Elisa Comaro, Vincenzo Canzonieri, Andrea Anichini, Michele Del Vecchio, Roberta Mortarini, Massimo Milione, Alessandro Weisz, Maria Antonietta Pizzichetta, Fiona Simpson, Riccardo Dolcetti, Elisabetta Fratta, Luca Sigalotti
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionAbout 50% of cutaneous melanoma (CM) patients present activating BRAF mutations that can be effectively targeted by BRAF inhibitors (BRAFi). However, 20% of CM patients exhibit intrinsic drug resistance to BRAFi, while most of the others
Externí odkaz:
https://doaj.org/article/9efcdcc70a744ed59d4d5235c051bf86
Autor:
Adele Busico, Monica Rodolfo, Lorenza Di Guardo, Michele Del Vecchio, Licia Rivoltini, Laura Bergamaschi, Viviana Vallacchi, Mario Santinami, Elisabetta Vergani, Mara Cossa, Chiara Gargiuli, Andrea Devecchi, Matteo Dugo, Loris De Cecco, Stefano Cavalieri, Barbara Valeri, Elena Tamborini, Gianfrancesco Gallino, Marialuisa Sensi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Durable remissions are observed in 10%–20% of treated patients with advanced metastatic melanoma but the factors associated with long-term complete clinical responses are largely unknown. Here, we report the molecular characteristics of tumor evolu
Externí odkaz:
https://doaj.org/article/6ee6e9735e44433696b169cef2b40458
Autor:
Paolo A. Ascierto, Eleonora Cioli, Vanna Chiarion-Sileni, Pietro Quaglino, Francesco Spagnolo, Massimo Guidoboni, Michele Del Vecchio, Ketty Peris, Paola Queirolo, Luisa Fioretto, Corrado Caracò, Miriam Paone, Antonio Sorrentino, Mariaelena Capone, Diana Giannarelli, Gerardo Ferrara, Daniela Massi, Claudia Trojaniello
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundFollowing the increased survival of patients with metastatic melanoma thanks to immunotherapy and targeted therapy, neoadjuvant approaches are being investigated to address the unmet needs of unresponsive and intolerant patients. We aim to
Externí odkaz:
https://doaj.org/article/881f19fac9d8492d94ad90ae1c453ee7
Autor:
Elisabetta Vergani, Matteo Dugo, Mara Cossa, Simona Frigerio, Lorenza Di Guardo, Gianfrancesco Gallino, Ilaria Mattavelli, Barbara Vergani, Luca Lalli, Elena Tamborini, Barbara Valeri, Chiara Gargiuli, Eriomina Shahaj, Marina Ferrarini, Elisabetta Ferrero, Macarena Gomez Lira, Veronica Huber, Michele Del Vecchio, Marialuisa Sensi, Biagio Eugenio Leone, Mario Santinami, Licia Rivoltini, Monica Rodolfo, Viviana Vallacchi
Publikováno v:
Cell Communication and Signaling, Vol 18, Iss 1, Pp 1-14 (2020)
Abstract Background Targeted therapy with BRAF and MEK inhibitors has improved the survival of patients with BRAF-mutated metastatic melanoma, but most patients relapse upon the onset of drug resistance induced by mechanisms including genetic and epi
Externí odkaz:
https://doaj.org/article/a1bcbc7c9c6f40e4a638028a386aaac5
Autor:
Filippo Balestra, Michele Del Vecchio, Dina Pirone, Maria Antonia Pedone, Danilo Spina, Salvatore Manfreda, Giovanni Menduni, Daniele Fabrizio Bignami
Publikováno v:
Environmental Sciences Proceedings, Vol 21, Iss 1, p 36 (2022)
This study suggests a rapid methodology to delineate areas prone to flood using machine learning techniques. Based on available historically flooded areas, the model employs and combines globally collectible and reproducible conditioning factors to a
Externí odkaz:
https://doaj.org/article/e6f7082d5d5540e5bf26048a4ebf2713
Autor:
James Larkin, Jeffrey Weber, Victoria Atkinson, Michael Millward, Ivan Marquez-Rodas, Luis de la Cruz-Merino, Helen Gogas, Paolo A Ascierto, Anna Maria Di Giacomo, Veerle de Pril, Vanna Chiarion-Sileni, Stephane Dalle, Leslie Fecher, Ana Arance, Jean-Jacques Grob, Nikhil I Khushalani, Michele Del Vecchio, Mario Mandala, C Lance Cowey, Michael Schenker, Petr Arenberger, Maurice Lobo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Externí odkaz:
https://doaj.org/article/c281f8a682984c818531f79c5352985a
Autor:
Daniela Massi, Eliana Rulli, Mara Cossa, Barbara Valeri, Monica Rodolfo, Barbara Merelli, Francesco De Logu, Romina Nassini, Michele Del Vecchio, Lorenza Di Guardo, Roberta De Penni, Michele Guida, Vanna Chiarion Sileni, Anna Maria Di Giacomo, Marco Tucci, Marcella Occelli, Francesca Portelli, Viviana Vallacchi, Francesca Consoli, Pietro Quaglino, Paola Queirolo, Gianna Baroni, Fabrizio Carnevale-Schianca, Laura Cattaneo, Alessandro Minisini, Giuseppe Palmieri, Licia Rivoltini, Mario Mandalà, on behalf of the Italian Melanoma Intergroup
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Clinical response to MAPK inhibitors in metastatic melanoma patients is heterogeneous for reasons still needing to be elucidated. As the patient immune activity contributes to treatment clinical benefit, the pre-existing level of
Externí odkaz:
https://doaj.org/article/11222a07bf7144359f4985d1307f24f9
Autor:
James Larkin, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M. Arance Fernandez, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Ivan Marquez-Rodas, Marcus O. Butler, Anna Maria Di Giacomo, Mark R. Middleton, Jose Lutzky, Luis de la Cruz-Merino, Petr Arenberger, Victoria Atkinson, Andrew G. Hill, Leslie A. Fecher, Michael Millward, Paul D. Nathan, Nikhil I. Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo A. Ascierto, Jeffrey Weber
Publikováno v:
Clinical Cancer Research. :OF1-OF10
Purpose: In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IV melanoma, with benefit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::434061b974def7d4b67a0e16b85e1b6e
https://doi.org/10.1158/1078-0432.ccr-22-3145
https://doi.org/10.1158/1078-0432.ccr-22-3145